摘要
Abstract
Objective:To study the application effect of TCbHP in neoadjuvant chemotherapy in elderly patients with her-2 positive breast cancer.Method:A total of 100 elderly patients with HER-2 positive breast cancer admitted to Suzhou University Affiliated Third Hospital from March 2020 to April 2022 were selected,they were randomly divided into the control group(n=50)and the observation group(n=50).The control group was given THP neoadjuvant chemotherapy,and the observation group was given TCbHP neoadjuvant chemotherapy.The clinical efficacy,tumor markers before and after treatment and adverse reactions were compared between the two groups.Result:The objective remission rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).After treatment,the levels of carcinoembryonic antigen and carbohydrate antigen 125 in two groups were lower than those before treatment,and the levels of carcinoembryonic antigen and carbohydrate antigen 125 in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).There were no significant differences in the incidence of thrombocytopenia,liver injury,alopecia,nausea and vomiting and hand-foot syndrome between two groups(P>0.05).Conclusion:Compared with THP,TCbHP can further inhibit the expression of tumor markers in elderly patients with HER-2 positive breast cancer,effectively control the development of disease,and will not aggravate the adverse reactions caused by chemotherapy.关键词
人表皮生长因子受体-2阳性/单抗/新辅助化疗/紫杉醇/乳腺癌Key words
Human epidermal growth factor receptor-2 positive/Monoclonal antibody/Neoadjuvant chemotherapy/Paclitaxel/Breast cancer
